266 related articles for article (PubMed ID: 27522631)
1. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.
Butler J; Hernandez AF; Anstrom KJ; Kalogeropoulos A; Redfield MM; Konstam MA; Tang WH; Felker GM; Shah MR; Braunwald E
JACC Heart Fail; 2016 Sep; 4(9):726-35. PubMed ID: 27522631
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.
Butler J; Anstrom KJ; Felker GM; Givertz MM; Kalogeropoulos AP; Konstam MA; Mann DL; Margulies KB; McNulty SE; Mentz RJ; Redfield MM; Tang WHW; Whellan DJ; Shah M; Desvigne-Nickens P; Hernandez AF; Braunwald E;
JAMA Cardiol; 2017 Sep; 2(9):950-958. PubMed ID: 28700781
[TBL] [Abstract][Full Text] [Related]
3. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
4. Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial.
Greene SJ; Felker GM; Giczewska A; Kalogeropoulos AP; Ambrosy AP; Chakraborty H; DeVore AD; Fudim M; McNulty SE; Mentz RJ; Vaduganathan M; Hernandez AF; Butler J
Can J Cardiol; 2019 Sep; 35(9):1097-1105. PubMed ID: 31230825
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
[TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.
Ferreira JP; Santos M; Almeida S; Marques I; Bettencourt P; Carvalho H
Eur J Intern Med; 2014 Jan; 25(1):67-72. PubMed ID: 24070521
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.
Desai AS; Lewis EF; Li R; Solomon SD; Assmann SF; Boineau R; Clausell N; Diaz R; Fleg JL; Gordeev I; McKinlay S; O'Meara E; Shaburishvili T; Pitt B; Pfeffer MA
Am Heart J; 2011 Dec; 162(6):966-972.e10. PubMed ID: 22137068
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
Yang P; Shen W; Chen X; Zhu D; Xu X; Wu T; Xu G; Wu Q
Heart Fail Rev; 2019 Sep; 24(5):637-646. PubMed ID: 31030322
[TBL] [Abstract][Full Text] [Related]
9. The Importance of Worsening Heart Failure in Ambulatory Patients: Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy.
Mallick A; Gandhi PU; Gaggin HK; Ibrahim N; Januzzi JL
JACC Heart Fail; 2016 Sep; 4(9):749-55. PubMed ID: 27179830
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study.
Myhre PL; Vaduganathan M; O'Meara E; Claggett BL; de Denus S; Jarolim P; Anand IS; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS
Circ Heart Fail; 2020 Jan; 13(1):e006638. PubMed ID: 31957468
[TBL] [Abstract][Full Text] [Related]
11. Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study.
Núñez J; Llàcer P; Bertomeu-González V; Bosch MJ; Merlos P; García-Blas S; Montagud V; Bodí V; Bertomeu-Martínez V; Pedrosa V; Mendizábal A; Cordero A; Gallego J; Palau P; Miñana G; Santas E; Morell S; Llàcer A; Chorro FJ; Sanchis J; Fácila L;
JACC Heart Fail; 2016 Nov; 4(11):833-843. PubMed ID: 27522630
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
Cox ZL; Collins SP; Aaron M; Hernandez GA; Iii ATM; Davidson BT; Fowler M; Lindsell CJ; Jr FEH; Jenkins CA; Kampe C; Miller KF; Stubblefield WB; Lindenfeld J
Am Heart J; 2021 Feb; 232():116-124. PubMed ID: 33144086
[TBL] [Abstract][Full Text] [Related]
14. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.
Kimmoun A; Cotter G; Davison B; Takagi K; Addad F; Celutkiene J; Chioncel O; Solal AC; Diaz R; Damasceno A; Duengen HD; Filippatos G; Goncalvesova E; Merai I; Metra M; Ponikowski P; Privalov D; Sliwa K; Sani MU; Voors AA; Shogenov Z; Mebazaa A
Eur J Heart Fail; 2019 Nov; 21(11):1459-1467. PubMed ID: 31423712
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
Pitt B; Anker SD; Bushinsky DA; Kitzman DW; Zannad F; Huang IZ;
Eur Heart J; 2011 Apr; 32(7):820-8. PubMed ID: 21208974
[TBL] [Abstract][Full Text] [Related]
16. Race influences the safety and efficacy of spironolactone in severe heart failure.
Vardeny O; Cavallari LH; Claggett B; Desai AS; Anand I; Rossignol P; Zannad F; Pitt B; Solomon SD;
Circ Heart Fail; 2013 Sep; 6(5):970-6. PubMed ID: 23940307
[TBL] [Abstract][Full Text] [Related]
17. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
[TBL] [Abstract][Full Text] [Related]
18. Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure.
Kociol RD; McNulty SE; Hernandez AF; Lee KL; Redfield MM; Tracy RP; Braunwald E; O'Connor CM; Felker GM;
Circ Heart Fail; 2013 Mar; 6(2):240-5. PubMed ID: 23250981
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
[TBL] [Abstract][Full Text] [Related]
20. Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect.
Ferreira JP; Girerd N; Medeiros PB; Santos M; Carvalho HC; Bettencourt P; Kénizou D; Butler J; Zannad F; Rossignol P
Clin Res Cardiol; 2016 Jun; 105(6):489-507. PubMed ID: 26615605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
